Osteoarthritis, Rheumatoid arthritis
Adult: 10 mg once daily.
Oral
Dysmenorrhoea
Adult: 20 mg bid.
Indications and Dosage
Oral
Osteoarthritis, Rheumatoid arthritis Adult: 10 mg once daily. Oral Dysmenorrhoea Adult: 20 mg bid.
|
||||
Renal Impairment
Oral:
Osteoarthritis,Rheumatoid arthritis:
|
||||
Hepatic Impairment
Child-Pugh scale 7-9: Initiate with caution. Child-Pugh scale >10: Avoid.
|
||||
Administration
May be taken with or without food.
|
||||
Contraindications
Hypersensitivity to sulfonamides, NSAIDs and other COX 2 inhibitors; asthma, urticaria; severe hepatic impairment; pregnancy (third trimester); lactation. Active GI bleed or ulceration, severe CHF, inflammatory bowel disease.
|
||||
Special Precautions
Mild to moderate hepatic impairment; history of ulcer disease or GI bleeding; dehydration, hypertension, history of heart failure, left ventricular dysfunction, pre-existing oedema. Monitor Hb or haematocrit values for signs and symptoms of anaemia.
|
||||
Adverse Reactions
Hypertension, back pain, myalgia, peripheral oedema, influenza-like symptoms, dizziness, headache, abdominal fullness, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, myalgia, sinusitis.
Potentially Fatal: Toxic epidermal necrolysis, exfoliative dermatitis. |
||||
PO: Z (NSAIDs caused foetal ductus arteriosus premature closure, foetal renal impairment and persistent pulmonary hypertension. Avoid near term, else use lowest dose for shortest time.), C
|
||||
Drug Interactions
Concomitant admin of aspirin may result in an increased risk of GI ulceration and complications. It decreases the antihypertensive effect of antihypertensives e.g. ACE inhibitors. It increases plasma conc of dextromethorphan. It significantly decreases lithium serum clearance and renal clearance.
|
||||
Action
Description: Valdecoxib acts by selectively inhibiting prostaglandin synthesis primarily by blocking cyclooxygenase (COX-2) enzyme. It was withdrawn worldwide in April 2005, following risk of serious skin reactions and cardiovascular side effects.
Onset: 60 min. Pharmacokinetics: Absorption: Peak plasma concentrations after 2.25-3 hrs (oral). Distribution: Protein-binding: 98% Metabolism: Extensively hepatic. Excretion: Urine (as metabolites); 8-11 hrs (elimination half-life). |
||||
Storage
Store below 30°C.
|
||||